PE20090983A1 - Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina - Google Patents

Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina

Info

Publication number
PE20090983A1
PE20090983A1 PE2008001892A PE2008001892A PE20090983A1 PE 20090983 A1 PE20090983 A1 PE 20090983A1 PE 2008001892 A PE2008001892 A PE 2008001892A PE 2008001892 A PE2008001892 A PE 2008001892A PE 20090983 A1 PE20090983 A1 PE 20090983A1
Authority
PE
Peru
Prior art keywords
residues
sequence identifier
similar
activin receptor
kinase
Prior art date
Application number
PE2008001892A
Other languages
English (en)
Inventor
Minhong Yan
Gu Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090983A1 publication Critical patent/PE20090983A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE AFECCIONES PATOLOGICAS ASOCIADAS CON LA LINFOANGIOGENESIS EN UN SUJETO TALES COMO TUMOR, CANCER, SARCOMA, LEUCEMIA, ARTRITIS REUMATOIDE, ENTRE OTROS, QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE i) UN ANTAGONISTA DE LA QUINASA-1 SIMILAR AL RECEPTOR DE LA ACTIVINA (ALK-1) TAL COMO UNA INMUNOADHESINA ALK-1 QUE COMPRENDE RESIDUOS DE AMINOACIDOS 22-352 DEL IDENTIFICADOR DE SECUENCIA Nº 2, RESIDUOS 22-349 DEL IDENTIFICADOR DE SECUENCIA Nº 4, RESIDUOS 22-347 DEL IDENTIFICADOR DE SECUENCIA Nº 6, RESIDUOS 22-350 DEL IDENTIFICADOR DE SECUENCIA Nº 8 O RESIDUOS 22-350 DEL IDENTIFICADOR DE SECUENCIA Nº 10; E ii) UN AGENTE ANTIANGIOGENICO TAL COMO BEVACIZUMAB
PE2008001892A 2007-11-09 2008-11-05 Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina PE20090983A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98687607P 2007-11-09 2007-11-09
US9855708P 2008-09-19 2008-09-19

Publications (1)

Publication Number Publication Date
PE20090983A1 true PE20090983A1 (es) 2009-08-13

Family

ID=40139964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001892A PE20090983A1 (es) 2007-11-09 2008-11-05 Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina

Country Status (20)

Country Link
US (3) US20090226441A1 (es)
EP (1) EP2217261B1 (es)
JP (1) JP5611047B2 (es)
KR (1) KR20100090683A (es)
CN (1) CN101918022A (es)
AR (1) AR070032A1 (es)
AU (1) AU2008324789A1 (es)
BR (1) BRPI0817063A2 (es)
CA (1) CA2703099A1 (es)
CL (1) CL2008003302A1 (es)
CO (1) CO6280405A2 (es)
ES (1) ES2554812T3 (es)
HK (1) HK1147434A1 (es)
IL (1) IL205247A0 (es)
MX (1) MX344733B (es)
PE (1) PE20090983A1 (es)
RU (1) RU2010123364A (es)
TW (1) TW200924796A (es)
WO (1) WO2009061807A2 (es)
ZA (1) ZA201002804B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
BRPI0717964A2 (pt) * 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
KR20180029111A (ko) * 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
EP2291401A2 (en) * 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
EA201791940A3 (ru) 2008-11-26 2018-04-30 Амген Инк. Варианты полипептидов рецептора iib активина и их использование
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
WO2011056497A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
CN104321070A (zh) * 2012-02-02 2015-01-28 艾科赛扬制药股份有限公司 Alk1拮抗剂及其在治疗肾细胞癌中的用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107405410B (zh) * 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017223495A1 (en) * 2016-06-24 2017-12-28 University Of South Carolina Inhibin as targetable regulators of angiogenesis
CN110177563A (zh) * 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR20200074201A (ko) * 2017-11-02 2020-06-24 바이엘 악티엔게젤샤프트 Alk-1 및 bmpr-2에 결합하는 이중특이적 항체
CN111372591A (zh) * 2017-11-21 2020-07-03 雀巢产品有限公司 调节alk的方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20080068151A (ko) * 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
EP2246333B1 (en) 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ME00425B (me) * 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
PL2960253T3 (pl) * 2005-09-07 2018-11-30 Amgen Fremont Inc. Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
KR20090016762A (ko) 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
BRPI0717964A2 (pt) * 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
KR20180029111A (ko) 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물

Also Published As

Publication number Publication date
CO6280405A2 (es) 2011-05-20
US20150250874A1 (en) 2015-09-10
KR20100090683A (ko) 2010-08-16
EP2217261B1 (en) 2015-10-07
AR070032A1 (es) 2010-03-10
US20090226441A1 (en) 2009-09-10
RU2010123364A (ru) 2011-12-20
ES2554812T3 (es) 2015-12-23
TW200924796A (en) 2009-06-16
CA2703099A1 (en) 2009-05-14
MX344733B (es) 2017-01-04
MX2010005056A (es) 2010-05-19
AU2008324789A1 (en) 2009-05-14
US20120171203A1 (en) 2012-07-05
WO2009061807A2 (en) 2009-05-14
WO2009061807A3 (en) 2009-09-24
JP2011503088A (ja) 2011-01-27
CL2008003302A1 (es) 2009-03-06
EP2217261A2 (en) 2010-08-18
JP5611047B2 (ja) 2014-10-22
HK1147434A1 (zh) 2011-08-12
ZA201002804B (en) 2011-07-27
CN101918022A (zh) 2010-12-15
IL205247A0 (en) 2010-12-30
US9066930B2 (en) 2015-06-30
BRPI0817063A2 (pt) 2015-03-24

Similar Documents

Publication Publication Date Title
PE20090983A1 (es) Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
MX2015007888A (es) Compuestos antivirales.
IN2012DN02652A (es)
BR112015013822A2 (pt) método de vaso único para a síntese de cu-ssz-13, o composto obtido através do método e utilização do mesmo
GT200500141A (es) Recubrimiento de azucar y metodos para la fabricacion de los mismos.
MX2018009085A (es) Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
GEP20125398B (en) Human monoclonal antibodies to activin receptor-like kinase-1
NI201000156A (es) Compuestos heterocíclicos novedosos y usos de los mismos.
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
SE1730346A1 (en) A hybrid photopolymer composition for additive manufacturing
MX2010000372A (es) Composiciones polimericas modificadas, proceso de modificacion y agentes generadores de radicales libres.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof

Legal Events

Date Code Title Description
FC Refusal